These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The inhibitory effect of bcl-2 antisense oligodeoxynucleotide/RNA on the growth of cervical carcinoma in vitro].
    Author: Mi R, Wang H, Qu Q.
    Journal: Zhonghua Fu Chan Ke Za Zhi; 2000 Feb; 35(2):105-8. PubMed ID: 11809111.
    Abstract:
    OBJECTIVE: To study the therapeutic effect of bcl-2 antisense oligodeoxynucleotide (ODN)/RNA human cervical carcinoma in vitro. METHODS: To transfect bcl-2 antisense ODN/RNA into Hela cells with antisense technology and observe the growth and apoptotic modulation of Hela cells. RESULTS: The expression of bcl-2 protein and mRNA was higher in Hela cells; the bcl-2 specific antisense ODN significantly decreased bcl-2 protein expression and inhibit the growth of Hela cells. The strongest inhibitory effect was at 24 hours after transfection, the optimal concentration of antisense ODN was 10 micromol/L. The results indicated that the inhibitory effect of bcl-2 antisense ODN on cell growth and survival rate is dose dependent; the recombinant retroviral vector pDOR-AB can transfer antisense bcl-2 gene into the genome of Hela cells, bcl-2 protein and mRNA expressions were significantly decreased after transfected, it demonstrated bcl-2 antisense RNA can significantly inhibit the growth of Hela cells and induce their apoptosis. CONCLUSION: The results demonstrate the feasibility of bcl-2 gene as a target for antisense gene therapy of human cervical carcinoma and provide the theoretical foundation and experimental evidence for further study in vivo.
    [Abstract] [Full Text] [Related] [New Search]